

P21480

Application No. 09/926,218

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Arne HOLMGREN et al.

Group Art Unit : 1621

Appl. No : 09/926,218

(National Stage of PCT/JP00/02076)

I.A. Filed : March 31, 2000

Examiner : Kumar

For : SUBSTRATE FOR THIOREDOXIN REDUCTASE

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AF
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir :

Further to the previously filed Information Disclosure Statements, Applicants hereby submit a copy of a Supplementary Partial European Search Report issued in connection with the counterpart European application on February 19, 2008.

Applicants note that this Supplementary Partial European Search Report cites the following document:

Engman et al., "Diaryl Chalcogenides as Selective Inhibitors of Thioredoxin Reductase and Potential Antitumor Agents", Anticancer Research, Hellenic Anticancer Institute, Athens, GR, Vol. 17, No. 6D, 1997, pp. 4599-4605 (listed as up to page 4606 in the Supplemental Partial European Search Report).

Since this Fourth Supplemental Information Disclosure Statement is being submitted subsequent to final rejection, Applicants have provided below a Statement Under 37 C.F.R. §

1.97(e), and a check including the amount of \$180.00 to cover the fee set forth in 37 C.F.R. § 1.17(p) is being submitted herewith in accordance with 37 C.F.R. § 1.97(d)(2). However, authorization is hereby provided to charge payment of any necessary fee associated with this communication or credit any overpayment to Deposit Account No. 19-0089.

In accordance with 37 C.F.R. 1.97(e), the undersigned hereby states that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

In particular, Applicants note that Engman et al. is already of record in the represent application as the Abstract having been cited as Engman et al., Anticancer Res. 1997 Nov-Dec;17(6D):4599-605 (Abstract), and entered in the record in the initialed Form PTO-1449 attached to Office Action mailed December 31, 2003. However, as discussed with the Examiner during a May 7, 2008 with the undersigned, a complete copy of Engman et al. as presently cited in the Supplementary Partial European Search Report is being submitted herewith certifying that the complete article is being cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider the complete copy of Engman et al., and to make it of record in this application by initialing in the appropriate space on the Form PTO-1449. Applicants respectfully request that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.


P21480

Application No. 09/926,218

As noted above, Applicants enclose \$180.00 in payment of the fee for consideration of this Information Disclosure Statement. If any fee is needed for consideration of the this paper and the information cited therein, authorization is hereby provided to charge any required fee, including any fee under 37 C.F.R. 1.17(p), to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted,
Arne HOLMGREN et al



Arnold Turk
Reg. No. 33,094

May 13, 2008
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191